Pharmacologic treatment of bronchial cancer - Part 1: Standards;Pharmakologische Therapie des Bronchialkarzinom - Teil I: Standards

Pneumologie

Volumn 60, Issue 8, 2006, Pages 493-508

  Serke, Monika ^a  

^a HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CLEMASTINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIPODOPHYLLOTOXIN; ETOPOSIDE; FLUOROPYRIMIDINE; FOLIC ACID ANTAGONIST; GEMCITABINE; IFOSFAMIDE; IMIPENEM; IRINOTECAN; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; RALTITREXED; TOPOTECAN; VINDESINE;

ALOPECIA; ARTICLE; BRONCHUS CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERSENSITIVITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TUMOR; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYALGIA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, BRONCHOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE;

EID: 33748487809     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-944265     Document Type: Article

References (39)

1. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909
2. Souquet PJ, Chauvin F, Boissel JP et al: Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21
3. Cullen MH, Billingham LJ, Woodroffe CM et al: Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-3194
4. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15: 2996-3018
5. Arriagada R, Bergman B, Dunant A et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall-cell lung cancer. N Eng J med 2004; 350: 351-360
6. Winton T, Livingston R, Johnson D et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597
7. Douillard JY, Rosell R, De Lena M et al: ANITA. A prospective randomized study of adjuvant chemotherapy with navelbine and cisplatin in completely resected non small cell lung cancer. ProcASCO 2005: 7013
8. Dillmann RO, Herndon J, Seagran SL et al: Improved survival in stage III NSCLC: seven-year follow up of CALGB 8433 trial. J Natl Cancer Inst 1996; 88: 1210-1215
9. Vokes EE, Herndon JE, Crawford J et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer. Cancer and leucemia group B study 9431. J Clin Oncol 2002; 20: 4191-4198
10. Hansen HH: Management of small cell cancer of the lung. Lancet 1992; 339: 846-849
11. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122-130
12. Wozniak AJ, Crowley JJ, Balcerzak SP et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459-2465
13. Gatzemeier U, Pawel J von, Gottfried M et al: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 3390-3399
14. Lilienimum RC, Langenberg P, Dickersin K: Single agent chemotherapy versus combination chemotherapy in patients with advanced NSCLC: A meta-analysis of response, toxi-city and survival. Cancer 1998; 82: 116-126
15. Horta K, Matsuo K, Ueoka H et al: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non small-cell lung cancer. J Clin Oncol 2004; 22: 3852-3853
16. Serke M, Schönfeld N, Loddenkemper R: Neue Zytostatika in der Therapie des Nicht-kleinzelligen Bronchialkarzinoms. Pneumologie 1998; 52: 333-337
17. Schiller JH, Harrington D, Belani CP et al: Comparison of 4 chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98
18. Cardenal F, Lopez-Cabrerizo P, Anton A et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic NSCLC. J Clin Oncol 1999; 17: 12-18
19. Le Chevaliier T, Brisgand D, Douillard JY et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367
20. GSMO Guideline Task Force: ESMO Minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Annals Oncology 2005; 16 (S1): i28-29
21. Eckhardt JR, Pawel J von, Papai Z et al: An open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naïve patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006; 24: 2044-2051
22. Noda K, Nishiwaki Y, Kawahara M et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Eng J Med 2002; 346: 85-91
23. Hanna N, Shepherd FA, Fossella FV et al: Randomized phase III trial of Pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597
24. D'Addario G, Pintilie M, Leighl N et al: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer. A meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-2936
25. Pujol JL, Barlesi F, Daures JP: Should chemotherapy combinations for advanced NSCLC be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006; 51: 335-345
26. Huhn D: Alkylantien. In: Huhn D, Hermann R (Hrsg). Medikamentöse Therapie maligner Erkrankungen, 3. Aufl. Stuttgart 2005: Fischer Verlag
27. Efferth T, Osieka R: Antineoplastische Substanzen: Substanzklassen und Wirkmechanismen. In: Schmoll, Höffken, Possinger (Hrsg). Kompendium internistische Onkologie, 4. Aufl. Heidelberg: Springer Verlag 2005
28. Colvin OM, Friedman HS: Alkylating agents. In: De Vita, Hellman, Rosenberg (ed). Cancer. Principles and Practice of Oncology, 7th ed. Philadelphia: Lippincott Williams + Wilkins 2005
29. Johnson SW, O'Dwyer PJ: Cisplatin and its analogues. In: De Vita, Hellman, Rosenberg (ed). Cancer. Principles and Practice of Oncology, 7th ed. Philadelphia: Lippincott Williams + Wilkins 2005
30. Bokemeyer C, Sökler M, Schmoll HJ et al: Begleittherapie bei Cisplatin. In: Schmoll, Höffken, Possinger (Hrsg). Kompendium internistische Onkologie, 4. Aufl. Heidelberg: Springer Verlag
31. Takimoto CH: Topoisomerase interactive agents. In: De Vita, Hellman, Rosenberg (ed). Principles and Practice of Oncology, 7th ed. Philadelphia: Lippincott Williams + Wilkins 2005
32. Possinger K: Anthracycline. In: Huhn D, Herrmann R (Hrsg). Medikamentöse Therapie maligner Erkrankungen, 3. Aufl. Stuttgart: Fischer Verlag
33. Rowinski EK, Tolcher AW: Antimicrotubule agents. In: De Vita, Hellman, Rosenberg (ed). Cancer. Principles and Practice of Oncology, 7th ed. Philadelphia: Lippincott Williams + Wilkins 2005
34. Kummar S, Noronha V, Chu E: Antimetabolites. In: De Vita, Hellman, Rosenberg (ed). Cancer. Principles and Practice of Oncology, 7th ed. Philadelphia: Lippincott Williams + Wilkins 2005
35. Crino L, Scagliotti GV, DeMarinos F et al: Gemcitabine and cisplatin versus Mitomycin, ifosfamide and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study if the Italian lung cancer project. J Clin Oncol 1999; 17 (11): 3522-3530
36. Gridelli C, Gallo C, Shepherd FA et al: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025-3034
37. Kosmidis P, Mylonakis N, Nicolaides C et al: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 2002; 20: 3578-3585
38. Souquet PJ, Tan EH, Pereira R et al: Glob-1: a prospective randomized clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamid-cisplatin in metastatic non small-cell lung caner patients. Ann Oncol 1857; 13 (12): 61
39. Schütte W, Nagel S, Blankenburg T et al: Phase III study of Second-Line Chemotherapy for Advanced NSCLC with weekly compared with 3-weekly Docetaxel. J Clin Oncol 2005; 23: 8389-8395